MX2007012702A - Uso de anticuerpos cd25 en inmunoterapia. - Google Patents

Uso de anticuerpos cd25 en inmunoterapia.

Info

Publication number
MX2007012702A
MX2007012702A MX2007012702A MX2007012702A MX2007012702A MX 2007012702 A MX2007012702 A MX 2007012702A MX 2007012702 A MX2007012702 A MX 2007012702A MX 2007012702 A MX2007012702 A MX 2007012702A MX 2007012702 A MX2007012702 A MX 2007012702A
Authority
MX
Mexico
Prior art keywords
immunotherapy
antibodies
administering
patient
treatment
Prior art date
Application number
MX2007012702A
Other languages
English (en)
Inventor
Andreas Katopodis
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2007012702A publication Critical patent/MX2007012702A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un metodo para el tratamiento de enfermedad proliferativa o enfermedad infecciosa, que comprende administrar al paciente una cantidad efectiva de una molecula de union de CD25.
MX2007012702A 2005-04-15 2006-04-13 Uso de anticuerpos cd25 en inmunoterapia. MX2007012702A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0507696.3A GB0507696D0 (en) 2005-04-15 2005-04-15 Organic compounds
PCT/EP2006/003444 WO2006108670A2 (en) 2005-04-15 2006-04-13 Use of cd25 antibodies in immunotherapy

Publications (1)

Publication Number Publication Date
MX2007012702A true MX2007012702A (es) 2008-01-14

Family

ID=34630783

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007012702A MX2007012702A (es) 2005-04-15 2006-04-13 Uso de anticuerpos cd25 en inmunoterapia.

Country Status (12)

Country Link
US (1) US20080171017A1 (es)
EP (1) EP1874349A2 (es)
JP (1) JP2008535883A (es)
KR (1) KR20070120146A (es)
CN (1) CN101160137A (es)
AU (1) AU2006233718A1 (es)
BR (1) BRPI0610635A2 (es)
CA (1) CA2600709A1 (es)
GB (1) GB0507696D0 (es)
MX (1) MX2007012702A (es)
RU (1) RU2007141994A (es)
WO (1) WO2006108670A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009542592A (ja) * 2006-07-06 2009-12-03 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｉｌ−２媒介性免疫応答の有効性を高める組成物および方法
WO2011077245A2 (en) * 2009-12-23 2011-06-30 Fondazione Centro San Raffaele Del Monte Tabor Compositions
CN103374074A (zh) * 2012-04-28 2013-10-30 中国科学院上海生命科学研究院 一种抗cd25单链抗体
NO3078372T3 (es) * 2013-07-18 2018-02-10
US11371066B2 (en) 2015-07-13 2022-06-28 Modular Genetics, Inc. Generation of acyl alcohols
BR112018070636A2 (pt) * 2016-04-07 2019-02-05 Cancer Research Tech Ltd método de tratamento de um sujeito humano que tem câncer, anticorpo, uso de um anticorpo, anticorpo para uso, combinação de um anticorpo, kit para uso no tratamento de câncer, composição farmacêutica, anticorpo biespecífico, método para tratamento de câncer, anticorpo biespecífico para uso e método de depleção de células t reguladoras em um tumor sólido em um sujeito
WO2018106931A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
CN108084263B (zh) * 2016-12-16 2021-07-13 苏州旭光科星抗体生物科技有限公司 一种抗人cd25嵌合单克隆抗体及其制备方法和应用
US11879014B2 (en) 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
EP4108183A1 (en) 2017-03-30 2022-12-28 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
PE20210289A1 (es) 2018-03-13 2021-02-11 Cancer Research Tech Ltd Anti-cd25 para el agotamiento de celulas tumorales especificas
EP3806888B1 (en) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
CN116726361A (zh) 2018-11-19 2023-09-12 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
EP3870261B1 (en) 2019-12-13 2024-01-31 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CN115397860A (zh) 2020-05-14 2022-11-25 江苏恒瑞医药股份有限公司 抗cd25抗体、其抗原结合片段及其医药用途
US20230381277A1 (en) * 2022-04-08 2023-11-30 Selecta Biosciences, Inc. High affinity il-2 receptor agonists and immunosuppressants to enhance immune tolerance
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT60768A (en) * 1990-03-16 1992-10-28 Sandoz Ag Process for producing cd25 fixing molecules
ATE372349T1 (de) * 1998-07-27 2007-09-15 Novartis Pharma Gmbh Verwendung von basiliximab zur behandlung von rheumatoider arthritis und hauterkrankungen
BR0208656A (pt) * 2001-04-06 2004-08-10 Univ Bristol Uso de moléculas ligantes de cd25 em pacientes resistentes a esteróides
CN101124244B (zh) * 2002-11-15 2012-10-10 根马布股份公司 抗cd25的人单克隆抗体

Also Published As

Publication number Publication date
GB0507696D0 (en) 2005-05-25
US20080171017A1 (en) 2008-07-17
WO2006108670A3 (en) 2006-12-28
JP2008535883A (ja) 2008-09-04
WO2006108670A2 (en) 2006-10-19
BRPI0610635A2 (pt) 2010-07-13
EP1874349A2 (en) 2008-01-09
CN101160137A (zh) 2008-04-09
RU2007141994A (ru) 2009-05-20
AU2006233718A1 (en) 2006-10-19
CA2600709A1 (en) 2006-10-19
KR20070120146A (ko) 2007-12-21

Similar Documents

Publication Publication Date Title
MX2007012702A (es) Uso de anticuerpos cd25 en inmunoterapia.
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
MX355181B (es) Anticuerpos humanos contra el factor tisular.
WO2008085562A3 (en) Combinatorieal therapy of cancer and infectious diseases with anti-b7-h1 antibodies
WO2007056540A3 (en) Tnf-alpha blocker treatment for enterocolitis associated with immunostimulatory therapeutic antibody therapy
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
TW200738270A (en) Method of treating depression using a TNFα antibody
MX2009005597A (es) Miembros de enlace para interleucina 6.
MX2009013656A (es) Composiciones terapeuticas anti-cd20 y metodos.
WO2009010877A3 (en) Conjugate purification
UA100507C2 (ru) Предупреждение и лечение субклинической формы болезней, вызываемых цирковирусом свиней (pcvd)
MX2010006823A (es) Metodos para el tratamiento de la gota.
MY147217A (en) Antibody molecules having specificity for human il-06
SG160412A1 (en) Anti-igfr1 antibody therapeutic combinations
UA100502C2 (ru) Лечение prdc с применением антигена pcv2
MY171841A (en) Antibody formulation
HK1243943A1 (zh) 使用抗IL-1α抗體治療癌症
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
MY151051A (en) Vaccination against dengue virus infection
SI2380584T1 (sl) Imunostimulatorni postopek
PL1934252T3 (pl) Sposób wytwarzania koniugatów insuliny
UA99601C2 (ru) Применение антитела к cd151 для лечения первичных опухолей
EP2468772A3 (en) Antibodies to EGFL7 and methods for their use
WO2010054377A3 (en) Fully human antibodies against n-cadherin
WO2010036567A3 (en) Harmine compounds for promoting bone growth

Legal Events

Date Code Title Description
FA Abandonment or withdrawal